Eshan Mehra

While powerful, medicine regularly waits for failure, letting disease manifest before intervening at emotional, financial, and physical costs. By then, the underlying biological decline has progressed for years, unseen. Training in cancer biology and public health, I understood why help arrives late: biological mechanisms of decline are hard to see and even harder to intervene in. Decline in health is not immediate but a gradual loss of regulation and accumulation of molecular damage shaped by environment, lifestyle, and stress. This loss is what we fail to understand and therefore fail to prevent.

It tracks with one variable above all: age. In the United States, the median cancer diagnosis comes at 66, the first heart attack near 65, and dementia at 83. Because many chronic diseases cluster in later years, therapeutic victories feel small. Cure every cancer and you add only two or three years to average lifespan, fewer still of quality, because often the same person meets another form of decline.

So I build tools to make underlying drivers of chronic diseases visible, focusing on methods that read how regulatory programs in individual cells drift off course before disease manifests.

The other half of the work is that this field is small on purpose. A few thousand scientists and roughly a billion dollars a year sit against the hundreds of billions spent treating disease after the damage is done. Insurers reimburse treatment, not prevention; trials are built around single diseases, not the drivers beneath them. Good ideas die twice, first in the gaps between people who never meet and then against incentives that make prevention nobody’s job.

So I build rooms too. Connective work is not peripheral to this science. In a field this young, it is how the science moves at all.